| 摘要 |
The objective of the present invention is to clarify the molecular mechanism underpinning the ligand-independent activation of EphA2 in cancer cells, to make EphA2 a more useful target for cancer treatment, and to provide a cancer examination method, etc. using said mechanism. The present invention provides a cancer examination method, etc., including a step for measuring the amount of EphA2 protein fragments having a molecular mass of 30-80kDA in a sample derived from a subject. |
